Product Description
Fosphenytoin is a medication used in the management and prevention of seizures. It is a water-soluble phenytoin prodrug with the capability to be used in situations where phenytoin is unadvised. It is in the hydantoin anticonvulsant class of medications. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK560745/)
Mechanisms of Action: Sodium Channel Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | Finland | France | Germany | Iceland | India | Ireland | Italy | Japan | Korea | New Zealand | Pakistan | Philippines | Slovenia | Sweden | Thailand | United Kingdom | United States
Approved Indications: Seizures | Status Epilepticus
Known Adverse Events: Ataxia | Dizziness | Pruritus
Company: Nobelpharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Acute Pain|Herpes Simplex|Herpes Zoster
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2041220047 | P3 |
Recruiting |
Herpes Zoster|Acute Pain |
2023-06-30 |
|
| NPC-06-6 | P3 |
Completed |
Herpes Zoster|Herpes Simplex|Acute Pain |
2023-05-29 |
95% |
| jRCT2031220593 | P1 |
Active, not recruiting |
Herpes Zoster|Acute Pain |
2023-03-31 |